 | Up a level |
Number of items: 1.
Galle, P. R., Kim, R. D., Sung, M. W., Harris, W. P., Waldschmidt, D., Cabrera, R., Mueller, U., Nakajima, K., Ishida, T. and El-Khoueiry, A. B. (2020). Updated results of a phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). Ann. Oncol., 31. S. S691 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041